NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DE-23-016 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit developmental/exploratory research to better understand the biology, natural history, and directionality of oral complications associated with pharmacotherapies used to treat opioid use disorders (OUDs). Further, this FOA will support research to explore access to care and other challenges that may contribute to dental and oral disease onset and progression in people with OUD.
Funding Opportunity RFA-DE-23-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit research to better understand the biology, natural history, and directionality of oral complications associated with pharmacotherapies used to treat opioid use disorders (OUDs). Further, this FOA will support research to address access to care and other challenges that may contribute to dental and oral disease onset and progression in people with OUD, with a long-term goal of developing targeted preventive strategies for these individuals.
Funding Opportunity RFA-HD-23-009 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites U.S. institutions to submit applications to participate in the Global Network for Womens and Childrens Health Researchs Data Coordinating Center. The Data Coordinating Center will work with Research Units of U.S.-based research centers partnering with institutions in low-income countries to conduct multi-center observational studies and randomized clinical trials evaluating disease process, health and wellness outcomes, and results from interventions in resource-poor settings to address the major causes of maternal, neonatal, infant, and early childhood morbidity and mortality. This Funding Opportunity Announcement (FOA) invites applications for a Global Network Data Coordinating Center; a separate FOA invites applications for Global Network Research Units.
Funding Opportunity RFA-HD-23-008 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites U.S. institutions in partnership with research centers in low-income countries to submit applications as Research Units (RUs) to participate in the Global Network for Womens and Childrens Health Research. RUs will consist of U.S.-based research centers applying as defined by the World Bank. The RU grantees will become part of a cooperative network in scientific partnership with the NIH to conduct multi-center observational studies and randomized clinical trials evaluating disease process, health and wellness outcomes, and results from interventions in resource-poor settings to address the major causes of maternal, neonatal, infant, and early childhood morbidity and mortality. This Funding Opportunity Announcement (FOA) invites applications for Global Network Research Units; a separate FOA invites applications for a Global Network Data Coordinating Center.
Notice NOT-OD-22-190 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-054 from the NIH Guide for Grants and Contracts. This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY23, this currently includes the Workforce NOSI (formerly an RFA) and the Violence and Trauma NOSI (also formerly an RFA). It has a companion R61/R33 RFA and is expected to run for 2 years (FY23 and FY24)
Funding Opportunity RFA-DA-23-053 from the NIH Guide for Grants and Contracts. This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY23, this currently includes the Workforce NOSI (formerly an RFA) and the Violence and Trauma NOSI (also formerly an RFA). It has a companion R33 RFA and is expected to run for 2 years (FY23 and FY24).
Notice NOT-NS-23-002 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-007 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-008 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-091 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-020 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-116 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-042 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-019 from the NIH Guide for Grants and Contracts. The purpose of the Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control) Funding Opportunity Announcement (FOA) is to build implementation science centers in low- and middle-income countries (LMICs). This initiative will support implementation science research capacity-building activities, including research projects that identify, develop, and test innovative theory-based strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based cancer control interventions (e.g., programs, tools, policies, and guidelines) in LMICs. NCI will support several U54 Specialized Centers with transdisciplinary research teams meaningfully collaborating with key stakeholders (e.g., health systems, ministries of health, clinicians, and communities) that must include at least one PI or MPI from an LMIC-based institution. This initiative aims to foster LMIC-based implementation science programs to inform implementation of cancer control efforts in LMICs.
Funding Opportunity RFA-NS-22-059 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.
Funding Opportunity RFA-DE-23-006 from the NIH Guide for Grants and Contracts. The goal of this FOA is to solicit applications to accelerate development, testing and implementation of advanced data-driven tools specifically designed to overcome critical problems affecting research and development (R and D) cycles that might contribute to delays in regulatory approval and human use of novel biomaterials for dental, oral, and craniofacial (DOC) applications. It is part of a suite of FOAs that encourage applicants to leverage the FDA-CDRHs Medical Device Development Tools (MDDT) Program framework as an innovative and important pathway to ensure that outcomes of funded studies yield practical and validated tools that are qualified by FDA to support a particular context-of-use. The overall objectives are to: 1) accelerate R and D cycles of biomaterials for DOC applications by de-risking potential safety and effectiveness uncertainties through robust and predictive preclinical characterization; 2) support technical developments and validation activities needed to satisfy the FDA MDDT qualification process for proposed data-driven tools; 3) promote multi-domain collaborations and empower workforce development at the intersection of data-driven technologies and biomaterial science in dentistry; and 4) build confidence in the use of data-driven technologies in biomaterials innovation by establishing pipelines of robust and validated tools that are qualified by FDA.
Funding Opportunity RFA-DE-23-007 from the NIH Guide for Grants and Contracts. The goal of this FOA is to solicit applications to accelerate development, testing and implementation of advanced data-driven tools specifically designed to overcome critical problems affecting research and development (R and D) cycles that might contribute to delays in regulatory approval and human use of novel biomaterials for dental, oral, and craniofacial (DOC) applications. It is part of a suite of FOAs that encourage applicants to leverage the FDA-CDRHs Medical Device Development Tools (MDDT) Program framework as an innovative and important pathway to ensure that outcomes of funded studies yield practical and validated tools that are qualified by FDA to support a particular context-of-use. The overall objectives are to: 1) accelerate R and D cycles of biomaterials for DOC applications by de-risking potential safety and effectiveness uncertainties through robust and predictive preclinical characterization; 2) support technical developments and validation activities needed to satisfy the FDA MDDT qualification process for proposed data-driven tools; 3) promote multi-domain collaborations and empower workforce development at the intersection of data-driven technologies and biomaterial science in dentistry; and 4) build confidence in the use of data-driven technologies in biomaterials innovation by establishing pipelines of robust and validated tools that are qualified by FDA.
Funding Opportunity RFA-DE-23-008 from the NIH Guide for Grants and Contracts. The goal of this FOA is to solicit applications to accelerate development, testing and implementation of advanced data-driven tools specifically designed to overcome critical problems affecting research and development (R and D) cycles that might contribute to delays in regulatory approval and human use of novel biomaterials for dental, oral, and craniofacial (DOC) applications. It is part of a suite of FOAs that encourage applicants to leverage the FDA-CDRHs Medical Device Development Tools (MDDT) Program framework as an innovative and important pathway to ensure that outcomes of funded studies yield practical and validated tools that are qualified by FDA to support a particular context-of-use. The overall objectives are to: 1) accelerate R and D cycles of biomaterials for DOC applications by de-risking potential safety and effectiveness uncertainties through robust and predictive preclinical characterization; 2) support technical developments and validation activities needed to satisfy the FDA MDDT qualification process for proposed data-driven tools; 3) promote multi-domain collaborations and empower workforce development at the intersection of data-driven technologies and biomaterial science in dentistry; and 4) build confidence in the use of data-driven technologies in biomaterials innovation by establishing pipelines of robust and validated tools that are qualified by FDA.
Notice NOT-CA-22-114 from the NIH Guide for Grants and Contracts